Target Gene Table
VIS IDVirusEnsembl IDGene TypeTarget GeneOncogeneTumor Suppressor GeneNCBI IDUniprot ID
TVIS30002482HIVENSG00000005844.19protein_codingITGALNoNo3683P20701
TVIS30074614HIVENSG00000005844.19protein_codingITGALNoNo3683P20701
TVIS30074615HIVENSG00000005844.19protein_codingITGALNoNo3683P20701
TVIS30019425HIVENSG00000005844.19protein_codingITGALNoNo3683P20701
TVIS30018938HIVENSG00000005844.19protein_codingITGALNoNo3683P20701
TVIS30019001HIVENSG00000005844.19protein_codingITGALNoNo3683P20701
TVIS30074617HIVENSG00000005844.19protein_codingITGALNoNo3683P20701
TVIS30040824HIVENSG00000005844.19protein_codingITGALNoNo3683P20701
TVIS30040825HIVENSG00000005844.19protein_codingITGALNoNo3683P20701
TVIS30040826HIVENSG00000005844.19protein_codingITGALNoNo3683P20701
TCGA Plot Options
Drug Information
GeneITGAL
DrugBank IDDB11611
Drug NameLifitegrast
Target IDBE0000516
UniProt IDP20701
Regulation Typeantagonist
PubMed IDs27883115
CitationsPaton DM: Lifitegrast: First LFA-1/ICAM-1 antagonist for treatment of dry eye disease. Drugs Today (Barc). 2016 Sep;52(9):485-493.
GroupsApproved
Direct ClassificationPhenylalanine and derivatives
SMILESCS(=O)(=O)C1=CC(C[C@H](NC(=O)C2=C(Cl)C3=C(CN(CC3)C(=O)C3=CC=C4C=COC4=C3)C=C2Cl)C(O)=O)=CC=C1
Pathways
PharmGKB
ChEMBLCHEMBL2048028